Health Care · Pharmaceutical Preparations

COLL COLLEGIUM PHARMACEUTICAL, INC SEC Filings & Insider Trading Activity 2026

company
CIK 1267565115 filings
Russell 2000

COLL at a glance

COLLEGIUM PHARMACEUTICAL, INC (COLL, SEC CIK 1267565) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), COLLEGIUM PHARMACEUTICAL, INC (COLL) reported revenue of $780.6 million (up 23.6% from FY2024) and net income of $62.9 million. Diluted EPS was $1.73.
  • As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding COLLEGIUM PHARMACEUTICAL, INC (COLL) shares worth $437.4 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Freund John Gordon on May 18, 2026 of 20 shares at $34.05 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$780.6M
+23.6% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
31 funds
$437.4M · −1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Commercializes differentiated biopharmaceutical products for ADHD and moderate to severe pain in the U.S.
  • New: September 2024 acquisition of Ironshore adds Jornay PM, expanding into neuropsychiatry and ADHD market
  • Strategic shift: Diversification beyond pain management to ADHD stimulation therapy with Jornay PM launch
  • Quantitative: Pain sales force ~105 reps; ADHD sales force ~200 reps targeting ~21,000 prescribers
  • Noteworthy: FDA granted pediatric exclusivity extensions up to January 2027 for Nucynta IR and December 2025 for Nucynta ER

Risk Factors

  • Cybersecurity risks overseen by Audit Committee with quarterly updates from Head of IT on incidents and infrastructure vulnerabilities
  • Potential impact from cybersecurity incidents managed by Head of IT with 20+ years experience and senior leadership for 10+ years
  • Operational risk from information technology infrastructure reliant on bi-weekly management meetings and established incident response plan

Management Discussion & Analysis

  • Revenue $780.6M in 2025, up $149.2M YoY from $631.4M; Jornay PM +$111.7M, Nucynta Products +$19.8M, Belbuca +$10.4M, Xtampza ER +$8.0M
  • Gross profit $463.3M vs $377.3M; operating expenses $284.8M vs $210.4M; operating income $179.6M vs $169.9M; operating margin ~23.0% vs ~26.9% (calculated from operating income/revenue)
  • Best segment: Jornay PM revenue $111.7M increase due to full year revenue in 2025 post-acquisition; worst: Symproic revenue down $0.7M
  • Cash & equivalents $231.3M at 2025 year-end vs $70.6M at 2024; 2025 Term Loan $580M outstanding with $29M due next 12 months; no detailed capex, buyback or dividend info provided
  • Management expects cash, cash equivalents, marketable securities plus operations to fund expenses, debt service, capex; risks include generic launch of Nucynta IR and ER impacting revenues

AI summary of the COLL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $216.3M, up $6.9M YoY from $209.4M
  • Operating margin 13.3% vs 29.6% YoY, net margin 10.1% vs 15.0%
  • Best product: Azstarys revenue $26.5M increase; worst: Nucynta Products revenue $24.0M decrease
  • Operating cash flow $215.0M, up from $206.3M; $655.4M Azstarys acquisition payment
  • Cash $144.8M; $50.0M accelerated share repurchase and $300.0M acquisition financing draw

Risk Factors

  • Newly added AI risk: internal and vendor AI use may expose confidential data or create inaccurate outputs, amid evolving U.S. and EU regulation
  • Most materially updated competition risk: Hikma launched Nucynta IR and ER generics on February 25, 2026 and March 11, 2026
  • Regulatory risk: FDA heightened promotional scrutiny in September 2025, increasing challenge risk for Xtampza ER advertising
  • Operational risk: sole manufacturer Patheon supplies Xtampza ER and Nucynta ER, creating disruption exposure
  • Financial risk: $854.5 million term loan plus $241.5 million convertible notes, with floating-rate debt unhedged

AI summary of the COLL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Collegium Pharmaceutical announced financial results for the quarter ended September 30, 2026
  • Full quarterly results and management commentary are contained in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Collegium released an earnings presentation on November 5, 2026
  • Presentation contains the company’s latest earnings-related information and investor messaging

Item EX-99.1: Item EX-99.1

  • Q3 revenue reached a record $216.3M, up 3% year over year, while adjusted EBITDA declined 9% to $121.6M
  • JORNAY PM revenue rose 24% to $51.9M, with prescriptions up 16% and prescribers up 19% to nearly 33,000

Item EX-99.2: Item EX-99.2

  • Q3’26 product revenue $216M, up 3% YoY, while adjusted EBITDA fell 9% to $122M on higher adjusted operating expenses
  • 2026 guidance maintained: product revenue $825–855M, adjusted EBITDA $445–470M
Filed Oct 19, 2026Full analysis →

Item 1.02: Termination of a Material Definitive Agreement

  • $17 million payment settles all disputes with Grünenthal, including Nucynta patent litigation
  • Grünenthal License terminated, eliminating future royalty obligations on Nucynta Products
Filed Aug 13, 2026Full analysis →

Item 8.01: Other Events

  • $50 million ASR with Jefferies, representing part of the $150 million repurchase program authorized in July 2025
  • Initial delivery of 1,556,420 shares, approximately 80% of expected ASR shares

AI summaries of COLL 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for COLL

Don't miss the next COLL filing

  • Alerts as it files. A push when COLL files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut COLL, by share count.
  • Ask anything. An AI agent that reads every COLL filing and answers with sources.

COLL alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Karnani VikramFNov 12, 2026$24.95
SANTINI GINOMJun 8, 2026-
SANTINI GINOMJun 8, 2026$16.49
Freund John GordonSellMay 18, 2026$34.05
Freund John GordonSellMay 15, 2026$34.54
Freund John GordonMMay 15, 2026-
Freund John GordonMMay 15, 2026$16.49
SANTINI GINOAMay 14, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$566.8M$631.4M$780.6M
Gross Profit-$377.3M$463.3M
Operating Income-$169.9M$179.6M
Net Income-$69.2M$62.9M
Gross Margin-59.8%59.3%
Op. Margin-26.9%23.0%
Net Margin-11.0%8.1%
Balance Sheet
Total Assets-$1.7B$1.7B
Equity$195.4M$228.8M$301.7M
ROE-30.2%20.8%
Per Share
EPS-$1.86$1.73
Cash Flow
Operating CF-$205.0M$329.3M
CapEx-$1.7M$1.7M

Source: XBRL data in COLLEGIUM PHARMACEUTICAL, INC (COLL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate COLL share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
COLL shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202631$437.4M
Q2 202632$690.2M
Q1 202632$606.1M
Q4 202530$813.1M
Q3 202529$633.4M
Q2 202529$521.3M
Q1 202527$395.2M
Q4 202423$337.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 233 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

COLL filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 19, 2026Analysis-
SC 13GAug 24, 2026-
SC 13GAug 14, 2026-
8-KAug 13, 2026Analysis-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
SC 13GAug 5, 2026-
SC 13GJul 31, 2026-
8-KJun 30, 2026Analysis-
4Jun 10, 2026-
4May 20, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
4May 18, 2026-
8-KMay 15, 2026Analysis
SC 13GMay 15, 2026-
4May 13, 2026-
8-KMay 12, 2026Analysis

Related Health Care companies

All Health Care →

COLL SEC filings: frequently asked questions

Which institutions hold COLL stock?

As of September 30, 2026, the largest COLLEGIUM PHARMACEUTICAL, INC (COLL) holders among the 13F filers tracked by SignalX were BlackRock ($118.9 million), Millennium Management ($52.4 million), State Street Corp ($38.7 million), Principal Financial Group ($33.0 million), Renaissance Technologies LLC ($30.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was COLL's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), COLLEGIUM PHARMACEUTICAL, INC (COLL) reported revenue of $780.6 million (up 23.6% from FY2024) and net income of $62.9 million. Diluted EPS was $1.73. The figures come from the XBRL data in the 10-K.

What are the main risks in COLL's latest 10-K?

In the 10-K filed February 26, 2026, COLLEGIUM PHARMACEUTICAL, INC (COLL) flagged: Cybersecurity risks overseen by Audit Committee with quarterly updates from Head of IT on incidents and infrastructure vulnerabilities. Potential impact from cybersecurity incidents managed by Head of IT with 20+ years experience and senior leadership for 10+ years. (AI summary of the Risk Factors section.)

What did COLL report in its latest 8-K?

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Collegium Pharmaceutical announced financial results for the quarter ended September 30, 2026.

What are the latest COLL SEC filings?

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 16, 2026.

What is COLL's SEC CIK number?

COLLEGIUM PHARMACEUTICAL, INC (COLL)'s SEC Central Index Key (CIK) is 1267565. EDGAR lists every COLL filing under that number.

Ask anything about COLL

The research agent reads COLL's filings, financials, insider trades and 13F holders, then answers with sources.